Glycerin

Glycerin

SCHEMBL3685666

C=CC.OCC(O)CO.OCCO

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
ALDH1A1 P00352 1/20 0.53
THRB P10828 1/20 0.43
TDP1 Q9NUW8 1/20 0.35
TSHR P16473 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycerin SCHEMBL550002 1.00 LMNA (0.53) LMNAALDH1A1THRBTDP1TSHR
Glycerin SCHEMBL19453124 0.97 LMNA (0.50) LMNAALDH1A1THRBTDP1
Glycerin SCHEMBL4330923 0.94 LMNA (0.60) LMNAALDH1A1THRBTDP1TSHR
Glycerin SCHEMBL343633 0.94
Glycerin SCHEMBL9770227 0.94 LMNA (0.60) LMNAALDH1A1THRBTDP1TSHR
Glycerin SCHEMBL13279055 0.94 LMNA (0.60) LMNAALDH1A1THRBTDP1TSHR
Glycerin SCHEMBL9770368 0.94 LMNA (0.60) LMNAALDH1A1THRBTDP1TSHR
Glycerin SCHEMBL10475823 0.94 LMNA (0.60) LMNAALDH1A1THRBTDP1TSHR
Glycerin SCHEMBL2674761 0.94 LMNA (0.60) LMNAALDH1A1THRBTDP1TSHR
Glycerin SCHEMBL29283590 0.91 LMNA (0.56) LMNAALDH1A1THRBTDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11337453-B2 Liquid aerosol formulation of an electronic smoking article ALTRIA CLIENT SERVICES LLC (US) 2022-05-24 US claimed
US-11141387-B2 Memantine-containing transdermally absorbable liquid MEDRX CO., LTD. (JP) 2021-10-12 US claimed
US-20200245678-A1 LIQUID AEROSOL FORMULATION OF AN ELECTRONIC SMOKING ARTICLE ALTRIA CLIENT SERVICES LLC (US) 2020-08-06 US claimed
US-10660365-B2 Liquid aerosol formulation of an electronic smoking article ALTRIA CLIENT SERVICES LLC (US) 2020-05-26 US claimed
US-20240016198-A1 WATER-BASED ELECTRONIC CIGARETTE LIQUID CHINA TOBACCO HUNAN INDUSTRIAL CO., LTD. (CN) 2024-01-18 US disclosed
WO-2023187868-A1 HIGH-DENSITY TOBACCO MOLDING 日本たばこ産業株式会社 2023-10-05 WO disclosed
WO-2023187871-A1 HIGH-DENSITY TOBACCO MOLDING 日本たばこ産業株式会社 2023-10-05 WO disclosed
WO-2023052995-A1 COMPOSITIONS WITH HIGH UREA CONTENT AND METHODS FOR BOOSTING ACTIVES L'OREAL (FR) 2023-04-06 WO disclosed
US-20230108443-A1 COSMETIC SKIN CONDITIONING COMPOSITION WITH HIGH UREA CONTENT L'OREAL (FR) 2023-04-06 US disclosed
EP-3840596-B1 COMPOSITION ZANOPRIMA LIFESCIENCES LTD (GB) 2023-02-08 EP disclosed
US-20230030621-A1 IMPROVED STABILITY INSECTICIDAL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME BASF SE (DE) 2023-02-02 US disclosed
WO-2023008063-A1 LIQUID FOR ELECTRONIC CIGARETTES, METHOD FOR MANUFACTURING LIQUID FOR ELECTRONIC CIGARETTES, CARTLIDGE FOR ELECTRONIC CIGARETTE AND ELECTRONIC CIGARETTE 株式会社北の達人コーポレーション 2023-02-02 WO disclosed
US-6071495-A TEMPERATURE ACTIVATED; PARTICULARLY USEFUL, FOR EXAMPLE, IN ULTRASONIC IMAGING APPLICATIONS AND IN THERAPEUTIC DRUG DELIVERY SYSTEMS. IMARX PHARMACEUTICAL CORP. (US) 2000-06-06 US disclosed
EP-0959908-A1 NOVEL TARGETED CONTRAST AGENTS FOR DIAGNOSTIC AND THERAPEUTIC USE IMARX PHARMACEUTICAL CORP. (US) 1999-12-01 EP disclosed
WO-1999013919-A1 NOVEL TARGETED CONTRAST AGENTS FOR DIAGNOSTIC AND THERAPEUTIC USE IMARX PHARMACEUTICAL CORP. (US) 1999-03-25 WO disclosed
US-5853752-A Methods of preparing gas and gaseous precursor-filled microspheres IMARX PHARMACEUTICAL CORP. (US) 1998-12-29 US disclosed
EP-0712293-A4 METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES UNGER EVAN C (US) 1998-05-06 EP disclosed
US-5585112-A TEMPERATURE-ACTIVATED FLUORINE-CONTAINING GAS; USEFUL IN ULTRASONIC IMAGING AND DRUG DELIVERY SYSTEMS; FDA ORANGE BOOK LISTED PATENT FOR PERFLUTREN IMARX PHARMACEUTICAL CORP. (US) 1996-12-17 US disclosed
EP-0712293-A1 METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES UNGER, Evan C (US) 1996-05-22 EP disclosed
WO-1994028780-A2 METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES UNGER EVAN C (US) 1994-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230108443-A1 COSMETIC SKIN CONDITIONING COMPOSITION WITH HIGH UREA CONTENT CUTA, SLC14A1, UTS2R LMNA 3653/4885ALDH1A1 871/4885THRB 3137/4885
US-20230030621-A1 IMPROVED STABILITY INSECTICIDAL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME ACHE, DDT, BCHE LMNA 2671/4885ALDH1A1 2462/4885THRB 4873/4885
US-11141387-B2 Memantine-containing transdermally absorbable liquid PHOSPHO1, TRPM7, TRPM8 LMNA 813/4885ALDH1A1 4195/4885THRB 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.